The body makes CoQ10 for its own energy machinery, and makes less with age and on cholesterol-lowering medication. Benefits concentrate in people who start out depleted or unwell — weakened hearts, disturbed blood sugar or blood fats, headaches, tiredness, fertility treatment. In people already well, the same doses move very little. Well tolerated; product quality is the weak link. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Plasma CoQ10 | 1.0–2.5 µg/mL general; >2.5 µg/mL for heart failure protocols | Confirms the product is absorbed at all |
| Seated blood pressure | <120/80 mmHg | Tracks the best-quantified benefit and the additive-hypotension risk |
| High-sensitivity C-reactive protein | <1.0 mg/L | Tracks the inflammation signal |
| Low-density lipoprotein cholesterol | <100 mg/dL, or <70 mg/dL with established vascular disease | Detects the small lipid shift and confirms statin efficacy is intact |
| HbA1c | 4.8–5.4% | Detects additive glucose lowering with diabetes medication |
| INR | Within the individual's warfarin target, usually 2.0–3.0 | The one interaction with a real safety consequence |
| NT-proBNP | <125 pg/mL under age 75; <450 pg/mL above | Tracks cardiac strain where heart failure is the reason for use |
| Serum selenium | 110–150 µg/L | Determines whether the combination rationale applies |
| ALT | 10–26 U/L women, 10–33 U/L men | Confirms no hepatic signal at sustained high doses |
Cadence: Baseline before starting; plasma CoQ10 and blood pressure retested at 8–12 weeks; INR at 2 and 4 weeks in warfarin users; annually thereafter, or every 6 months if the dose changes or a statin is started or stopped